middle.news

How Noxopharm’s HERACLES Trial Success Could Transform Autoimmune Treatment

9:18am on Friday 30th of January, 2026 AEDT Biotechnology
Read Story

How Noxopharm’s HERACLES Trial Success Could Transform Autoimmune Treatment

9:18am on Friday 30th of January, 2026 AEDT
Key Points
  • HERACLES trial dosing successfully completed with positive safety results
  • New Material Transfer Agreement signed with overseas partner for autoimmune therapeutics
  • First US patent granted for Sofra immune-modulatory oligonucleotides
  • Victorian Government recognition highlights strategic collaboration
Read Story
middle.

Tap to Read

Tap the card to read the full analysis
about NOXOPHARM (ASX:NOX)
OPEN ARTICLE